Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Antifungal F2G Raises $60m, Sees Harmonized Route To Market

Executive Summary

UK-based antifungal company F2G has raised $60m as it prepares a pivotal trial of its lead drug candidate for the treatment of invasive fungal infections. With both oral and IV formulations of its lead candidate and a harmonized regulatory pathway agreed with the US FDA and EMA, CEO Ian Nicholson believes a 2019 filing is achievable.


Related Content

VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
Antifungal firm F2G attracts Novartis despite Neutec flop





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst